FDA panel’s ruling on naproxen’s link to blood clots
Victoria Richards, associate professor of medical sciences at the Frank H. Netter MD School of Medicine at Quinnipiac University, is available to discuss a FDA medical panel's Feb. 11 ruling that naproxen, sold as Aleve, does not pose a lower risk of cardiovascular blood clots than other common pain medications such as Advil, Celebrex and ibuprofen.
"The panel's decision is not really surprising," Richards, an expert in pharmacology and toxicology, told USA Today Tuesday. "To say naproxen is safer, I think that would be a slippery slope for the FDA and consumers."
Richards earned her doctorate in pharmacology and toxicology from the University of Arizona.
To arrange an interview with Richards, please contact John Morgan, associate vice president for public relations, at 203-206-4449.